Unlocking beta cell health: The clinical potential of extracellular vesicles in type 1 diabetes

Abstract

Background: Type 1 diabetes (T1D) is a lifelong autoimmune disease characterised by progressive immune-mediated destruction of insulin-producing beta (β)T1D-cells, leading to permanent insulin dependence and increased risk of microvascular and macrovascular complications. Despite advances in autoantibody screening and immunotherapies, major clinical challenges persist in early detection, accurate disease staging, prediction of progression and monitoring of therapeutic response. Current biomarkers provide limited insight into real-time β-cell stress and immune activity, restricting opportunities for timely and personalised intervention.

Rationale: Extracellular vesicles (EVs) are nano-sized membrane-bound particles released by virtually all cell types and carry proteins, lipids and nucleic acids reflective of their cellular origin and physiological state. Advances in EV isolation, multi-omics profiling and bioinformatics now enable detailed characterisation of EV cargo from accessible biofluids such as blood and urine. These developments position EVs as a minimally invasive platform to interrogate β-cell health, immune activation and systemic complications in T1D, while also offering a novel class of cell-free immunomodulatory therapeutics.

Content: This review synthesises current evidence on the role of EVs in T1D pathogenesis and clinical translation. We discuss how β-cell- and immune cell-derived EVs participate in antigen presentation, immune activation and inflammatory amplification, and how EV cargo signatures (proteins, miRNAs and other RNAs) reflect disease stage, progression and heterogeneity. We summarise emerging data on maternal, neonatal and urinary EVs as early-life and complication-associated biomarkers, and critically evaluate ongoing EV-based clinical studies in T1D. Finally, we examine the therapeutic potential of stem cell-derived and engineered EVs to modulate autoimmunity and preserve residual β-cell function.

Conclusion: EVs introduce a potentially clinically actionable layer of information linking cellular stress, immune dysregulation and tissue damage to measurable biomarkers and therapeutic opportunities in T1D. However, the majority of EV applications currently remain at the preclinical or early pilot‑study stage, with limited validation in large, longitudinal patient cohorts. Key challenges include biological heterogeneity, assay reproducibility and the need for standardised isolation, characterisation and regulatory frameworks. While rapid advances in EV technologies and early proof‑of‑concept clinical studies support their long‑term potential, substantial work is required before routine clinical implementation is feasible. For feasible clinical translation of EV-based applications, alignment with regulatory frameworks must be considered early to ensure analytical validity, standardisation and compliance with clinical and diagnostic approval pathways, as well as to address safety, efficacy and manufacturing requirements for EV-based therapeutics.

Key points:

Keywords

biomarkers / extracellular vesicles / immunomodulation / precision medicine / type 1 diabetes

References

[1] Duncan B, Magliano D, Boyko E. IDF Diabetes Atlas 11th edition 2025: global prevalence and projections for 2050. Nephrol Dial Transplant. 2025; 41(1): 7-9.

[2] Quattrin T, Mastrandrea L, Walker L. Type 1 diabetes. Lancet. 2023; 401(10394): 2149-2162.

[3] Phillip M, Achenbach P, Addala A, et al. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetologia. 2024; 67(9): 1731-1759.

[4] Haller MJ, Bell KJ, Besser RE, et al. ISPAD Clinical Practice Consensus Guidelines 2024: screening, staging, and strategies to preserve beta-cell function in children and adolescents with type 1 diabetes. Horm Res Paediatr. 2024; 97(6): 529-545.

[5] Joshi K, Harris M, Cotterill A, et al. Continuous glucose monitoring has an increasing role in pre-symptomatic type 1 diabetes: advantages, limitations, and comparisons with laboratory-based testing. Clin Chem Lab Med. 2024; 62(1): 41-49.

[6] Felton JL, Griffin KJ, Oram RA, et al. Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic review. Commun Med (Lond). 2023; 3(1): 130.

[7] Herold KC, Bundy BN, Long SA, et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019; 381(7): 603-613.

[8] So M, Vogrin S, Waibel M, Kay TW, Wentworth JM. β-Cell function derived from routine clinical measures reports and predicts treatment response to immunotherapy in recent-onset type 1 diabetes. Diabetes Care. 2025; 48(8): 1370-1376.

[9] Sydney G, Wu S, Herold K. Moving the goalposts closer: using intermediate end points in type 1 diabetes prevention trials. Diabetes Care. 2025; 48(8): 1318-1319.

[10] Evans-Molina C, Dor Y, Lernmark Å, et al. The heterogeneity of type 1 diabetes: implications for pathogenesis, prevention, and treatment—2024 diabetes. Diabetes Care, andDiabetologiaExpert Forum Diabetologia. 2025; 68(9): 1859-1878.

[11] Bernáth-Nagy D, Kalinyaprak MS, Giannitsis E, et al. Circulating extracellular vesicles as biomarkers in the diagnosis, prognosis and therapy of cardiovascular diseases. Frontiers in Cardiovascular Medicine. 2024; 11: 2024.

[12] Cruz CG, Sodawalla HM, Mohanakumar T, Bansal S. Extracellular vesicles as biomarkers in infectious diseases. Biology. 2025; 14(2): 182.

[13] Boukouris S, Mathivanan S. Exosomes in bodily fluids are a highly stable resource of disease biomarkers. Proteomics Clin Appl. 2015; 9(3-4): 358-367.

[14] Nair S, Razo-Azamar M, Jayabalan N, et al. Advances in extracellular vesicles as mediators of cell-to-cell communication in pregnancy. Cytokine & Growth Factor Reviews. 2024; 76: 86-98.

[15] Suire C, Hade M. Extracellular vesicles in type 1 diabetes: a versatile tool. Bioengineering (Basel). 2022; 9(3): 105.

[16] Saint-Pol J, Culot M. Minimum information for studies of extracellular vesicles (MISEV) as toolbox for rigorous, reproducible and homogeneous studies on extracellular vesicles. Toxicology in Vitro. 2025; 106:106049.

[17] Simons M, Raposo G. Exosomes–vesicular carriers for intercellular communication. Current opinion in cell biology. 2009; 21(4): 575-581.

[18] Wen SW, Lima LG, Lobb RJ, et al. Breast cancer-derived exosomes reflect the cell-of-origin phenotype. Proteomics. 2019; 19(8):1800180.

[19] Minagar A, Jy W, Jimenez JJ, et al. Elevated plasma endothelial microparticles in multiple sclerosis. Neurology. 2001; 56(10): 1319-1324.

[20] Li W, Liu S, Chen Y, et al. Circulating exosomal microRNAs as biomarkers of systemic lupus erythematosus. Clinics (Sao Paulo). 2020; 75:e1528.

[21] Rydland A, Heinicke F, Nyman TA, et al. Newly-diagnosed rheumatoid arthritis patients have elevated levels of plasma extracellular vesicles with protein cargo altered towards inflammatory processes. Scientific Reports. 2025; 15(1):11632.

[22] LEON-GUTIERREZ R, ARIYARATNE GHDN, LIANG Z, et al. 1225-P: identification of novel extracellular vesicle–based circulating biomarkers for type 1 diabetes. Diabetes. 2025; 74(Supplement_1).

[23] Mazzeo A, Beltramo E, Lopatina T, Gai C, Trento M, Porta M. Molecular and functional characterization of circulating extracellular vesicles from diabetic patients with and without retinopathy and healthy subjects. Experimental Eye Research. 2018; 176: 69-77.

[24] Sabatier F, Darmon P, Hugel B, et al. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes. 2002; 51(9): 2840-2845.

[25] Garcia-Contreras M, Shah SH, Tamayo A, et al. Plasma-derived exosome characterization reveals a distinct microRNA signature in long duration Type 1 diabetes. Scientific Reports. 2017; 7(1): 5998.

[26] Saravanan PB, Vasu S, Yoshimatsu G, et al. Differential expression and release of exosomal miRNAs by human islets under inflammatory and hypoxic stress. Diabetologia. 2019; 62(10): 1901-1914.

[27] Vomund AN, Zinselmeyer BH, Hughes J, et al. Beta cells transfer vesicles containing insulin to phagocytes for presentation to T cells. Proc Natl Acad Sci U S A. 2015; 112(40): E5496-502.

[28] Cianciaruso C, Phelps EA, Pasquier M, et al. Primary human and rat β-cells release the intracellular autoantigens GAD65, IA-2, and proinsulin in exosomes together with cytokine-induced enhancers of immunity. Diabetes. 2017; 66(2): 460-473.

[29] Hasilo CP, Negi S, Allaeys I, et al. Presence of diabetes autoantigens in extracellular vesicles derived from human islets. Sci Rep. 2017; 7(1): 5000.

[30] Ebert M, Sharp P. Roles for microRNAs in conferring robustness to biological processes. Cell. 2012; 149(3): 515-524.

[31] Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011; 13(4): 423-433.

[32] Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011; 39(16): 7223-7233.

[33] Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9(6): 654-659.

[34] Thomou T, Mori MA, Dreyfuss JM, et al. Adipose-derived circulating miRNAs regulate gene expression in other tissues. Nature. 2017; 542(7642): 450-455.

[35] Lakhter AJ, Pratt RE, Moore RE, et al. Beta cell extracellular vesicle miR-21-5p cargo is increased in response to inflammatory cytokines and serves as a biomarker of type 1 diabetes. Diabetologia. 2018; 61(5): 1124-1134.

[36] Sims EK, Lakhter AJ, Anderson-Baucum E, Kono T, Tong X, Evans-Molina C. MicroRNA 21 targets BCL2 mRNA to increase apoptosis in rat and human beta cells. Diabetologia. 2017; 60(6): 1057-1065.

[37] Richardson SJ, Rodriguez-Calvo T, Gerling IC, et al. Islet cell hyperexpression of HLA class I antigens: a defining feature in type 1 diabetes. Diabetologia. 2016; 59(11): 2448-2458.

[38] Rondas D, Crèvecoeur I, D'Hertog W, et al. Citrullinated glucose-regulated protein 78 is an autoantigen in type 1 diabetes. Diabetes. 2014; 64(2): 573-586.

[39] Mannering SI, Harrison LC, Williamson NA, et al. The insulin A-chain epitope recognized by human T cells is posttranslationally modified. J Exp Med. 2005; 202(9): 1191-1197.

[40] Toren E, Burnette KS, Banerjee RR, Hunter CS, Tse HM. Partners in crime: beta-cells and autoimmune responses complicit in type 1 diabetes pathogenesis. Frontiers in Immunology. 2021; 12: 2021.

[41] James EA, Joglekar AV, Linnemann AK, Russ HA, Kent SC. The beta cell-immune cell interface in type 1 diabetes (T1D). Mol Metab. 2023; 78:101809.

[42] Rutman AK, Negi S, Gasparrini M, Hasilo CP, Tchervenkov J, Paraskevas S. Immune response to extracellular vesicles from human islets of langerhans in patients with type 1 diabetes. Endocrinology. 2018; 159(11): 3834-3847.

[43] Javeed N, Her TK, Brown MR, et al. Pro-inflammatory β cell small extracellular vesicles induce β cell failure through activation of the CXCL10/CXCR3 axis in diabetes. Cell Rep. 2021; 36(8):109613.

[44] Marin-Gallen S, Clemente-Casares X, Planas R, et al. Dendritic cells pulsed with antigen-specific apoptotic bodies prevent experimental type 1 diabetes. Clin Exp Immunol. 2010; 160(2): 207-214.

[45] Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020; 10(3): 727-742.

[46] Colli ML, Hill JL, Marroquí L, et al. PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-α and-γ via IRF1 induction. EBioMedicine. 2018; 36: 367-375.

[47] Yoshihara E, O'Connor C, Gasser E, et al. Immune-evasive human islet-like organoids ameliorate diabetes. Nature. 2020; 586(7830): 606-611.

[48] Rao C, Cater DT, Roy S, et al. Beta cell extracellular vesicle PD-L1 as a novel regulator of CD8(+) T cell activity and biomarker during the evolution of type 1 diabetes. Diabetologia. 2025; 68(2): 382-396.

[49] Casu A, Nunez Lopez YO, Yu G, et al. The proteome and phosphoproteome of circulating extracellular vesicle-enriched preparations are associated with characteristic clinical features in type 1 diabetes. Front Endocrinol (Lausanne). 2023; 14:1219293.

[50] Tesovnik T, Kovač J, Pohar K, et al. Extracellular vesicles derived human-miRNAs modulate the immune system in type 1 diabetes. Frontiers in Cell and Developmental Biology. 2020; 8: 202.

[51] Giri KR, de Beaurepaire L, Jegou D, et al. Molecular and functional diversity of distinct subpopulations of the stressed insulin-secreting cell's vesiculome. Frontiers in Immunology. 2020; 11: 1814.

[52] Salama A, Fichou N, Allard M, et al. MicroRNA-29b modulates innate and antigen-specific immune responses in mouse models of autoimmunity. PloS one. 2014; 9(9):e106153.

[53] Sun Y, Zhou Y, Shi Y, et al. Expression of miRNA-29 in pancreatic β cells promotes inflammation and diabetes via TRAF3. Cell reports. 2021; 34(1):108576.

[54] Brown W, Clancy S, Translation: DNA to mRNA to Protein. 2008.

[55] Prieto-Vila M, Yoshioka Y, Ochiya T. Biological functions driven by mRNAs carried by extracellular vesicles in cancer. Frontiers in Cell and Developmental Biology. 2021; 9: 2021.

[56] Kalani A, Chaturvedi S, Chaturvedi P. Wilms’ tumor 1 in urinary exosomes as a non-invasive biomarker for diabetic nephropathy. Clinica Chimica Acta. 2026; 579:120599.

[57] Hashemi E, Dehghanbanadaki H, Baharanchi AA, et al. WT1 and ACE mRNAs of blood extracellular vesicle as biomarkers of diabetic nephropathy. Journal of Translational Medicine. 2021; 19(1): 299.

[58] Fan W, Pang H, Shi X, et al. Plasma-derived exosomal mRNA profiles associated with type 1 diabetes mellitus. Front Immunol. 2022; 13:995610.

[59] Mirza AH, Kaur S, Nielsen LB, et al. Breast milk-derived extracellular vesicles enriched in exosomes from mothers with type 1 diabetes contain aberrant levels of microRNAs. Front Immunol. 2019; 10: 2543.

[60] Frørup C, Mirza AH, Yarani R, et al. Plasma exosome-enriched extracellular vesicles from lactating mothers with type 1 diabetes contain aberrant levels of miRNAs during the postpartum period. Frontiers in Immunology. 2021; 12: 2021.

[61] Bjornstad P, Cherney D, Maahs D. Early diabetic nephropathy in type 1 diabetes: new insights. Curr Opin Endocrinol Diabetes Obes. 2014; 21(4): 279-286.

[62] Berrabeh S, Elmehraoui O, Benouda S, Assarrar I, Rouf S, Latrech H. Prevalence and risk factors of retinopathy in type 1 diabetes: a cross-sectional study. Cureus. 2023; 15(10):e47993.

[63] Gimenez-Perez G, Vlacho B, Navas E, et al. Comorbid autoimmune diseases and burden of diabetes-related complications in patients with type 1 diabetes from a Mediterranean area. Diabetes Research and Clinical Practice. 2022; 191:110031.

[64] Samuelsson J, Bertilsson R, Bülow E, et al. Autoimmune comorbidity in type 1 diabetes and its association with metabolic control and mortality risk in young people: a population-based study. Diabetologia. 2024; 67(4): 679-689.

[65] Currie G. Biomarkers in diabetic nephropathy: present and future. World J Diabetes. 2014; 5(6): 763-776.

[66] Ting DSW, Tan K, Phua V, Tan GSW, Wong CW, Wong TY. Biomarkers of diabetic retinopathy. Current Diabetes Reports. 2016; 16(12): 125.

[67] Berezin A. Biomarkers for cardiovascular risk in patients with diabetes. Heart. 2016; 102(24): 1939-1941.

[68] Lytvyn Y, Xiao F, Kennedy CRJ, et al. Assessment of urinary microparticles in normotensive patients with type 1 diabetes. Diabetologia. 2017; 60(3): 581-584.

[69] Gkiourtzis N, Stoimeni A, Michou P, et al. The NGAL as a prognostic biomarker of kidney injury in children and adolescents with type 1 diabetes mellitus: a systematic review and meta-analysis. Journal of Diabetes and its Complications. 2025; 39(5):109002.

[70] Ugarte F, Santapau D, Gallardo V, et al. Urinary extracellular vesicles as a source of NGAL for diabetic kidney disease evaluation in children and adolescents with type 1 diabetes mellitus. Front Endocrinol (Lausanne). 2021; 12:654269.

[71] Kalani A, Mohan A, Godbole MM, et al. Wilm's tumor-1 protein levels in urinary exosomes from diabetic patients with or without proteinuria. PLOS ONE. 2013; 8(3):e60177.

[72] Musante L, Tataruch D, Gu D, et al. Proteases and protease inhibitors of urinary extracellular vesicles in diabetic nephropathy. J Diabetes Res. 2015; 2015:289734.

[73] Barutta F, Tricarico M, Corbelli A, et al. Urinary exosomal microRNAs in incipient diabetic nephropathy. PLOS ONE. 2013; 8(11):e73798.

[74] Bergen K, Mobarrez F, Jörneskog G, Wallén H, Tehrani S. High levels of endothelial and platelet microvesicles in patients with type 1 diabetes irrespective of microvascular complications. Thromb Res. 2020; 196: 78-86.

[75] Zhang J, Chen L, Wang F, et al. Extracellular HMGB1 exacerbates autoimmune progression and recurrence of type 1 diabetes by impairing regulatory T cell stability. Diabetologia. 2020; 63(5): 987-1001.

[76] Théry C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nature reviews immunology. 2009; 9(8): 581-593.

[77] Favaro E, Carpanetto A, Caorsi C, et al. Human mesenchymal stem cells and derived extracellular vesicles induce regulatory dendritic cells in type 1 diabetic patients. Diabetologia. 2016; 59(2): 325-333.

[78] Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. Jama. 2013; 309(23): 2473-2479.

[79] Xu P, Beam CA, Cuthbertson D, Sosenko JM, Skyler JS, Krischer JP. Prognostic accuracy of immunologic and metabolic markers for type 1 diabetes in a high-risk population: receiver operating characteristic analysis. Diabetes Care. 2012; 35(10): 1975-1980.

[80] Sosenko JM, Skyler JS, Palmer JP, et al. The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diabetes Care. 2013; 36(9): 2615-2620.

[81] Jacobsen LM, Felton JL, Nathan BM, Speake C, Krischer J, Herold KC. Type 1 diabetes TrialNet: leading the charge in disease prediction, prevention, and immunotherapeutic mechanistic understanding. Diabetes Care. 2025; 48(7): 1112-1124.

[82] Nakayasu ES, Bramer LM, Ansong C, et al. Plasma protein biomarkers predict the development of persistent autoantibodies and type 1 diabetes 6 months prior to the onset of autoimmunity. Cell Rep Med. 2023; 4(7):101093.

[83] Joglekar MV, Wong WKM, Kunte PS, et al. A microRNA-based dynamic risk score for type 1 diabetes. Nature Medicine. 2025; 31(8): 2622-2631.

[84] Alqaderi H, Batorsky R, Azar G, et al. Comparative machine learning analysis of saliva and plaque microbiomes in kuwaitis with type 1 diabetes. Frontiers in Microbiology; 17:1735375.

[85] Zimmerman S, Tierney BT, Nguyen VK, Kostic AD, Patel CJ. Specification curve analysis of the TEDDY study reveals large variation in microbiome-based T1D predictive performance. Nat Commun. 2025; 16(1): 9526.

[86] Sassi G, Lemaitre P, Calvo LF, et al. Neutrophil-enriched gene signature correlates with teplizumab therapy resistance in different stages of type 1 diabetes. J Clin Invest. 2025; 135(23):e176403.

[87] Alshamsi F, Pathan A, Yasin J, et al. Urinary C-peptide creatinine ratio as a non-invasive diagnostic tool for differentiating type 1 from type 2 diabetes mellitus in adult Emirati population: a prospective validation study. Frontiers in Endocrinology. 2025; 16: 2025.

[88] Conkright WR, Beckner ME, Sterczala AJ, et al. Resistance exercise differentially alters extracellular vesicle size and subpopulation characteristics in healthy men and women: an observational cohort study. Physiological Genomics. 2022; 54(9): 350-359.

[89] Kargl CK, Sterczala AJ, Santucci D, et al. Circulating extracellular vesicle characteristics differ between men and women following 12 weeks of concurrent exercise training. Physiol Rep. 2024; 12(9):e16016.

[90] Noren Hooten N, Byappanahalli AM, Vannoy M, Omoniyi V, Evans MK. Influences of age, race, and sex on extracellular vesicle characteristics. Theranostics. 2022; 12(9): 4459-4476.

[91] Martens-Uzunova ES, Kusuma GD, Crucitta S, et al. Androgens alter the heterogeneity of small extracellular vesicles and the small RNA cargo in prostate cancer. J Extracell Vesicles. 2021; 10(10):e12136.

[92] Salehi R, Wyse BA, Asare-Werehene M, et al. Androgen-induced exosomal miR-379-5p release determines granulosa cell fate: cellular mechanism involved in polycystic ovaries. J Ovarian Res. 2023; 16(1): 74.

[93] Yan L, Yang Z, Lin H, Jiang J, Jiang R. Effects of androgen on extracellular vesicles from endothelial cells in rat penile corpus cavernosum. Andrology. 2021; 9(3): 1010-1017.

[94] Drula R, Pardini B, Fu X, et al. 17β-estradiol promotes extracellular vesicle release and selective miRNA loading in ERα-positive breast cancer. Proc Natl Acad Sci U S A. 2023; 120(23):e2122053120.

[95] Fafián-Labora J, Lesende-Rodriguez I, Fernández-Pernas P, et al. Effect of age on pro-inflammatory miRNAs contained in mesenchymal stem cell-derived extracellular vesicles. Sci Rep. 2017; 7:43923.

[96] Yin Y, Chen H, Wang Y, Zhang L, Wang X. Roles of extracellular vesicles in the aging microenvironment and age-related diseases. J Extracell Vesicles. 2021; 10(12):e12154.

[97] Riquelme JA, Takov K, Santiago-Fernández C, et al. Increased production of functional small extracellular vesicles in senescent endothelial cells. Journal of Cellular and Molecular Medicine. 2020; 24(8): 4871-4876.

[98] Zhang X, Ma S, Huebner JL, et al. Immune system-related plasma extracellular vesicles in healthy aging. Frontiers in Immunology. 2024; 15: 2024.

[99] Bettin B, Gasecka A, Li B, et al. Removal of platelets from blood plasma to improve the quality of extracellular vesicle research. Journal of Thrombosis and Haemostasis. 2022; 20(11): 2679-2685.

[100] Ríos de los Ríos Reséndiz J, Herrmann-Sim F, Wilkesmann L, et al. A translational protocol optimizes the isolation of plasma-derived extracellular vesicle proteomics. Scientific Reports. 2025; 15(1):24292.

[101] Welsh JA, Goberdhan DCI, O'Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024; 13(2):e12404.

[102] Ahmadian S, Jafari N, Tamadon A, Ghaffarzadeh A, Rahbarghazi R, Mahdipour M. Different storage and freezing protocols for extracellular vesicles: a systematic review. Stem Cell Res Ther. 2024; 15(1): 453.

[103] Pierri B, Eitan E, Witwer KW, Re DB, Baccarelli AA, Wu H. Tissue-specific extracellular vesicles enriched from circulation: exploring the liquid biopsy perspective. J Extracell Biol. 2026; 5(2):e70106.

[104] Auber M, Svenningsen P. An estimate of extracellular vesicle secretion rates of human blood cells. J Extracell Biol. 2022; 1(6):e46.

[105] Li Y, He X, Li Q, et al. EV-origin: enumerating the tissue-cellular origin of circulating extracellular vesicles using exLR profile. Computational and Structural Biotechnology Journal. 2020; 18: 2851-2859.

[106] Zanganeh S, Arias GF, Cone AS, Yuan R, Dittmer DP. Protocol for large-scale, high-yield, high-purity extracellular vesicle purification from human plasma. STAR Protoc. 2026; 7(1):104428.

[107] Akbar A, Malekian F, Baghban N, Kodam SP, Ullah M. Methodologies to isolate and purify clinical grade extracellular vesicles for medical applications. Cells. 2022; 11(2): 186.

[108] Talebjedi B, Tasnim N, Hoorfar M, Mastromonaco GF, De Almeida Monteiro Melo Ferraz M. Exploiting microfluidics for extracellular vesicle isolation and characterization: potential use for standardized embryo quality assessment. Frontiers in Veterinary Science. 2021; 7: 2020.

[109] Meggiolaro A, Moccia V, Brun P, et al. Microfluidic strategies for extracellular vesicle isolation: towards clinical applications. Biosensors (Basel). 2022; 13(1): 50.

[110] Jiawei S, Zhi C, Kewei T, Xiaoping L. Magnetic bead-based adsorption strategy for exosome isolation. Frontiers in Bioengineering and Biotechnology. 2022; 10: 2022.

[111] Ha E, Han Y, Kim M, Gerelkhuu Z, Kwon SJ, Yoon TH. Quantum dot-based immunolabelling of extracellular vesicles and detection using fluorescence-based nanoparticle tracking analysis. J Extracell Biol. 2025; 4(7):e70072.

[112] Boriachek K, Islam MN, Gopalan V, Lam AK, Nguyen N, Shiddiky MJA. Quantum dot-based sensitive detection of disease specific exosome in serum. Analyst. 2017; 142(12): 2211-2219.

[113] Bai Y, Lu Y, Wang K, et al. Rapid isolation and multiplexed detection of exosome tumor markers via queued beads combined with quantum dots in a microarray. Nano-Micro Letters. 2019; 11(1): 59.

[114] Bordanaba-Florit G, Royo F, Kruglik SG, Falcón-Pérez JM. Using single-vesicle technologies to unravel the heterogeneity of extracellular vesicles. Nature Protocols. 2021; 16(7): 3163-3185.

[115] Tran HL, Zheng W, Issadore DA, et al. Extracellular vesicles for clinical diagnostics: from bulk measurements to single-vesicle analysis. ACS Nano. 2025; 19(31): 28021-28109.

[116] Sharma H, Sahlot R, Purwar N, et al. Co-existence of type 1 diabetes and other autoimmune ailments in subjects with autoimmune thyroid disorders. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2022; 16(2):102405.

[117] Zou J, Peng H, Liu Y. The roles of exosomes in immunoregulation and autoimmune thyroid diseases. Frontiers in Immunology. 2021; 12: 2021.

[118] Flores Monar G, Islam H, Puttagunta SM, et al. Association between type 1 diabetes mellitus and celiac disease: autoimmune disorders with a shared genetic background. Cureus. 2022; 14(3):e22912.

[119] Efthymakis K, Bologna G, Simeone P, et al. Circulating extracellular vesicles are increased in newly diagnosed celiac disease patients. Nutrients. 2022; 15(1): 71.

[120] Chauhan R, al e. Global prevalence and clinical correlates of obesity in children and adolescents with type 1 diabetes: a systematic review and meta-analysis. 2026; 23(1): 396.

[121] Jeong I, Kim O. Pathophysiological roles of obesity-induced alterations in extracellular vesicles derived from adipose tissue and adipocytes. Current Obesity Reports. 2026; 15(1): 7.

[122] Gesmundo I, Pardini B, Gargantini E, et al. Adipocyte-derived extracellular vesicles regulate survival and function of pancreatic β cells. JCI Insight. 2021; 6(5):e14196.

[123] Potakowskyj I, Bagarić I, Prodanović N, et al. Enrichment of immune cell-derived extracellular vesicles from plasma using 35 and 70 nm size-exclusion chromatography columns of different sizes. J Extracell Biol. 2025; 4(11):e70098.

[124] Becker MW, Peters LD, Myint T, et al. Immune engineered extracellular vesicles to modulate T cell activation in the context of type 1 diabetes. Sci Adv. 2023; 9(22):eadg1082.

[125] Jimenez DE, Tahir M, Faheem M, et al. Comparison of four purification methods on serum extracellular vesicle recovery, size distribution, and proteomics. Proteomes. 2023; 11(3): 23.

[126] Esparza D, Lima C, Abuelreich S, et al. Pancreatic β-cells package double C2-like domain beta protein into extracellular vesicles via tandem C2 domains. Frontiers in Endocrinology. 2024; 15: 2024.

[127] Guthalu Kondegowda N, Cisneros Z, Roeth D, et al. Proinflammatory circulating extracellular vesicles from type 1 diabetes patients contribute to beta cell cytotoxicity and disease pathogenicity. bioRxiv. 2025.

[128] Garcia-Contreras M, Shah SH, Tamayo A, et al. Plasma-derived exosome characterization reveals a distinct microRNA signature in long duration Type 1 diabetes. Sci Rep. 2017; 7(1): 5998.

[129] Nojehdehi S, Soudi S, Hesampour A, Rasouli S, Soleimani M, Hashemi SM. Immunomodulatory effects of mesenchymal stem cell-derived exosomes on experimental type-1 autoimmune diabetes. J Cell Biochem. 2018; 119(11): 9433-9443.

[130] Korutla L, Rickels MR, Hu RW, et al. Noninvasive diagnosis of recurrent autoimmune type 1 diabetes after islet cell transplantation. Am J Transplant. 2019; 19(6): 1852-1858.

RIGHTS & PERMISSIONS

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.